US · GYRE
Gyre Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Diego, CA 92130
- Website
- gyretx.com
Price · as of 2024-12-31
$7.80
Market cap 748.94M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $89.00 | +1,041.03% |
| Intrinsic Value(DCF) | $19.27 | +147.05% |
| Graham-Dodd Method(GD) | $1.45 | -81.36% |
| Graham Formula(GF) | $0.23 | -97.04% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $5,429.89 | $33,199.79 | $30,268.28 | $538.33 | $9,606.63 |
| 2011 | $1,389.35 | $6,323.34 | $166,775.83 | $436.90 | $0.00 |
| 2012 | $850.74 | $908.49 | $651.10 | $442.02 | $678.14 |
| 2013 | $932.58 | $2,190.87 | $255.08 | $0.00 | $11,894.20 |
| 2014 | $502.45 | $414.73 | $227.35 | $0.00 | $8,137.74 |
| 2015 | $75.06 | $1,749.37 | $50.32 | $0.00 | $0.00 |
| 2016 | $15.96 | $6.38 | $0.00 | $0.00 | $1,429.81 |
| 2017 | $68.42 | $41.24 | $7.34 | $0.00 | $0.00 |
| 2018 | $19.19 | $25.93 | $7.08 | $0.00 | $233.03 |
| 2019 | $13.91 | $19.82 | |||
| 2020 | $15.01 | $0.68 | $0.00 | ||
| 2021 | $1.59 | $21.09 | $0.00 | $0.00 | $155.09 |
| 2022 | $3.00 | $193.64 | $74.80 | $0.70 | $37.38 |
| 2023 | $17.24 | $67.68 | $18.44 | $0.00 | $0.00 |
| 2024 | $10.32 | $89.00 | $46.61 | $1.45 | $0.23 |
AI valuation
Our deep-learning model estimates Gyre Therapeutics, Inc.'s (GYRE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $89.00
- Current price
- $7.80
- AI upside
- +1,041.03%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$19.27
+147.05% upside
Graham-Dodd
$1.45
-81.36% upside
Graham Formula
$0.23
-97.04% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GYRE | Gyre Therapeutics, Inc. | $7.80 | 748.94M | +1,041% | +147% | -81% | -97% | 49.07 | 13.87 | 8.30 | 47.88 | — | 14.25 | 96.33% | 15.28% | 11.43% | 75.37% | -233.28% | 14.80% | 0.03 | — | 3.32 | 2.86 | -0.57 | -10355.00% | -678.00% | -13911.00% | -0.77% | -0.19 | 126.74% | 0.00% | 0.00% | 0.00% | 52.78 | -126.03 | 8.07 | 20.39 |
| ATXS | Astria Therapeutics, Inc. | $12.58 | 718.13M | — | — | — | — | -3.69 | 1.09 | — | -0.26 | — | 1.09 | 0.00% | — | — | -33.52% | 3380.03% | -31.58% | 0.02 | — | 17.49 | 17.15 | 0.58 | -3058.00% | — | 1908.00% | -23.45% | -4.25 | 2470.44% | 0.00% | 0.00% | 0.00% | -0.22 | -0.30 | — | 6.30 |
| AVBP | ArriVent BioPharma, Inc. … | $22.97 | 948.23M | — | — | — | — | -8.55 | 2.67 | — | -5.83 | -47.58 | 2.67 | 0.00% | — | — | -39.36% | -469.29% | -36.75% | 0.00 | — | 13.14 | 12.70 | 0.92 | 1797.00% | — | 2573.00% | -10.20% | -4.06 | -349.38% | 0.00% | 0.00% | 0.00% | -4.98 | -6.69 | — | 22.46 |
| AVXL | Anavex Life Sciences Corp… | $4.43 | 410.54M | — | — | — | — | -8.09 | 3.96 | — | -5.88 | -210.39 | 3.96 | 0.00% | — | — | -43.11% | 523.72% | -38.75% | 0.00 | — | 11.60 | 11.56 | 2.21 | 385.00% | — | 2672.00% | -10.40% | -4.36 | 397.76% | 0.00% | 0.00% | 0.00% | -5.30 | -6.98 | — | 19.47 |
| CTMX | CytomX Therapeutics, Inc. | $5.37 | 909.87M | +2,414% | -87% | -65% | +202% | 1.76 | -123.14 | 0.41 | -1.31 | — | -28.25 | 100.00% | 18.10% | 23.08% | -133.06% | -16.56% | 19.77% | -20.58 | — | 1.25 | 1.21 | -1.07 | -503506.00% | 3645.00% | 5216.00% | -154.12% | -1.01 | 57.76% | 0.00% | 0.00% | 45.36% | -1.40 | 0.41 | -0.25 | -5.71 |
| ERAS | Erasca, Inc. | $13.66 | 4.23B | — | — | — | — | -2.21 | 0.84 | — | -0.73 | — | 0.84 | 0.00% | — | — | -43.68% | -151.38% | -36.01% | 0.12 | — | 9.84 | 9.58 | 0.10 | -1687.00% | — | 2814.00% | -36.89% | -3.49 | -111.24% | 0.00% | 0.00% | 0.00% | -0.62 | -0.84 | — | 0.06 |
| IOVA | Iovance Biotherapeutics, … | $3.86 | 1.28B | +666% | -61% | — | — | -3.46 | 1.94 | 5.14 | -3.10 | — | 3.23 | 97.23% | -153.08% | -148.38% | -55.50% | -89.67% | -42.88% | 0.07 | — | 3.20 | 2.74 | 0.32 | -1484.00% | 6060.00% | -764.00% | -24.83% | -2.19 | -75.14% | 0.00% | 0.00% | 4.22% | -2.74 | -3.29 | 4.20 | -1.24 |
| KROS | Keros Therapeutics, Inc. | $14.19 | 575.24M | +2,117% | -32% | — | — | -2.27 | 0.75 | 120.01 | 0.62 | — | 0.75 | 100.00% | -5938.96% | -5277.55% | -41.46% | -916.80% | -38.01% | 0.03 | — | 21.45 | 20.56 | 2.91 | -385.00% | 225099.00% | 2822.00% | -38.21% | -5.86 | -707.93% | 0.00% | 0.00% | 52.66% | 0.55 | 0.71 | -32.40 | 4.44 |
| MBX | MBX Biosciences, Inc. Com… | $32.55 | 1.09B | — | — | — | — | -5.33 | 1.28 | — | -1.00 | -6.55 | 1.28 | 0.00% | — | — | -66.95% | 86.67% | -35.11% | 0.00 | — | 24.19 | 23.78 | 0.72 | 8137.00% | — | 7303.00% | -16.82% | -4.95 | 70.61% | 0.00% | 0.00% | 5.75% | -1.00 | -1.23 | — | 17.45 |
| MGTX | MeiraGTx Holdings plc | $7.56 | 608.51M | +360% | -66% | — | — | -3.01 | 6.57 | 13.39 | -3.51 | -7.13 | 6.65 | 28.51% | -493.44% | -444.10% | -143.48% | -223.66% | -49.55% | 1.25 | -12.37 | 2.03 | 1.88 | 0.15 | 4228.00% | 13742.00% | -1282.00% | -24.57% | -1.72 | -149.07% | 0.00% | 0.00% | 0.00% | -2.60 | -3.90 | 12.82 | -3.93 |
| MLTX | MoonLake Immunotherapeuti… | $17.51 | 1.24B | — | — | — | — | -4.97 | 3.74 | — | -3.74 | -5.73 | 3.74 | 0.00% | — | — | -60.99% | 4029.60% | -50.78% | 0.25 | -33.78 | 9.27 | 8.77 | 1.18 | 8677.00% | — | 6740.00% | -17.20% | -4.31 | 3226.55% | 0.00% | 0.00% | 7.13% | -3.36 | -4.19 | — | 3.33 |
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
- CEO
- Ping Zhang
- Employees
- 579
- Beta
- 7.05
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($19.27 ÷ $7.80) − 1 = +147.05% (DCF, example).